Novo, Lilly, Merck and Mannkind
Hmmmm... which backstabbing has been diabetes company seems to not be sponsoring a seminar?
Hopefully Mannkind will get good attendance. This should be a gauge of how much interest STAT has stirred up. I assume if attendance is high MNKD will tweet about it.
Sanofi is sponsoring four symposia --
professional.diabetes.org/sites/professional.diabetes.org/files/media/css_at-a-glance-ss18-5.1.18.pdfFRIDAY, JUNE 22, 2018:
6:30 p.m.–9:10 p.m.
The Foundational Role of Physiologic, Long‐Acting Basal Insulin—Optimizing the Safety‐Efficacy Equation in Vulnerable Patients with Type 2 Diabetes
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes
(6:30 p.m.–7:00 p.m.–Dinner/7:00 p.m.–9:10 p.m.–Program)
This program will focus on the role, indications, guidelines, and evidence supporting optimal approaches to early use, dosing, switching to, and intensification of physiologic, long-acting basal insulin therapy for type 2 diabetes, and when appropriate, in combination with other therapies; and, provide an individualized and patient needs-specific “evidence-based roadmap,” consistent with ADA/EASD position.
Location: Hyatt Regency Orlando, Regency Ballroom O-R
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net
6:30 p.m.-9:15 p.m.
The Mechanistic and Therapeutic Rationale for Dual SGLT1/2 Inhibition in Adults with Type 1 Diabetes
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes
(6:30 p.m.–7:00 p.m.–Dinner/7:00 p.m.–9:15 p.m.–Program)
This CME activity will focus on the role, indications, guidelines, and evidence supporting optimal approaches for improving comprehensive glycemic management, HbA1c target goal attainment, safety, and metabolic optimizing by using agents with mechanistic complementarity with insulin, including those therapies acting through dual SGLT1/2 inhibition, in adults with type 1 diabetes mellitus.
Location: Hyatt Regency Orlando, Regency Ballroom S-V
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net
SATURDAY, JUNE 23, 2018:
6:15 p.m.-9:15 p.m.
Multi-Mechanistic, Insulin-Based Approaches for Achieving HbA1c/PPG Targets and Optimizing Safety in Challenging Patients with Type 2 Diabetes
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes
(6:15 p.m.–6:45 p.m.–Dinner/6:45 p.m.–9:15 p.m.–Program)
This CME activity will focus on the role, indications, guidelines, and evidence supporting “multi-mechanistic” approaches to early use, conversion to, and titration of combination insulin therapy and fixed ratio GLP-combinations; as well as the use of insulin-based formulations in fixed-ratio combination with GLP-1 receptor agonists to optimize metabolic and compliance end points.
Location: Hyatt Regency Orlando, Regency Ballroom O-R
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net
6:15 p.m.-9:15 p.m.
The Landmark Evidence and Clinical Rationale for PCSK9 Inhibition in the Diabetic Patient
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi and Regeneron
(6:15 p.m.–6:45 p.m.–Dinner/6:45 p.m.–9:15 p.m.–Program)
This CME activity will focus on landmark clinical cardiovascular outcomes trials, mechanisms of atherosclerotic heart disease, new ACC/ECDP Task Force Guidelines for non‐statin‐based LDL reduction, novel LDL targets and therapies, and new translational dimensions of applying new cardiovascular outcome data in PCSK9‐mediated LDL reduction to the diabetic population.
Location: Hyatt Regency Orlando, Regency Ballroom S-V
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net
